ABILIFY MYCITE: payments to doctors
Payments that named ABILIFY MYCITE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.6M
- Providers
- 3,502
- Transactions
- 10,874
- Average per transaction
- $147
The per-transaction average — $147 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,502 providers the average total is $457, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,034,338 | 64.6% |
| Otsuka America Pharmaceutical, Inc. | $567,243 | 35.4% |